Human Major Histocompatibility Complex class II (HLA-II) (HLA-II)

The Human MHC class II peptide-binding groove is a critical structural feature of the Major Histocompatibility Complex class II (HLA-II) molecules, including HLA-DR, HLA-DQ, and HLA-DP, found on the surface of professional antigen-presenting cells. Formed by the alpha-1 and beta-1 domains of the HLA-II heterodimer, the groove possesses an open-ended structure that accommodates exogenous peptides typically 13 to 25 amino acids in length. Its primary biological function is to present these peptides to CD4+ T helper cells, thereby initiating and regulating the adaptive immune response. In disease states, the groove is central to the development of autoimmune disorders, where specific HLA alleles present self-peptides, and in oncology, where tumors may downregulate MHC II or fail to remove the CLIP peptide to evade immune detection. Therapeutic strategies targeting the groove include peptide mimetics like glatiramer acetate, which competitively bind the site to treat multiple sclerosis, and small molecules like methyldopa that can block specific pockets to prevent the presentation of pathogenic antigens. Due to the high polymorphism of HLA-II alleles, targeting the groove requires high specificity to avoid broad immunosuppression or off-target immune activation.

Other names

Human Leukocyte Antigen class IIMHC class IIHLA class IIMHC-II peptide-binding cleftHLA-DR/DQ/DP peptide-binding pocket

Competitive inhibition of peptide binding and modulation of T-cell receptor (TCR) recognition by occupying the peptide-binding groove.